OP Asset Management Ltd Invests $1.07 Million in Solventum Corporation $SOLV

OP Asset Management Ltd bought a new stake in Solventum Corporation (NYSE:SOLV) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 16,419 shares of the company’s stock, valued at approximately $1,072,000.

Several other large investors have also modified their holdings of the stock. PKO Investment Management Joint Stock Co bought a new stake in Solventum in the first quarter valued at about $98,000. SG Americas Securities LLC grew its position in shares of Solventum by 38.4% in the 1st quarter. SG Americas Securities LLC now owns 129,663 shares of the company’s stock worth $8,467,000 after acquiring an additional 35,982 shares in the last quarter. Strong Tower Advisory Services grew its position in shares of Solventum by 4.9% in the 1st quarter. Strong Tower Advisory Services now owns 112,703 shares of the company’s stock worth $7,360,000 after acquiring an additional 5,295 shares in the last quarter. Hsbc Holdings PLC increased its holdings in shares of Solventum by 2.3% in the 4th quarter. Hsbc Holdings PLC now owns 227,139 shares of the company’s stock valued at $18,021,000 after acquiring an additional 5,015 shares during the last quarter. Finally, Rockefeller Capital Management L.P. increased its holdings in shares of Solventum by 15.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 6,450 shares of the company’s stock valued at $511,000 after acquiring an additional 864 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Rothschild & Co Redburn initiated coverage on Solventum in a research note on Tuesday, March 24th. They set a “sell” rating and a $60.00 price objective on the stock. Stifel Nicolaus lowered their target price on shares of Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Piper Sandler dropped their target price on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Wall Street Zen downgraded shares of Solventum from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Finally, KeyCorp lifted their price target on shares of Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Eight equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $84.25.

Solventum Stock Down 1.7%

Shares of Solventum stock opened at $78.21 on Tuesday. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75. Solventum Corporation has a 1-year low of $62.38 and a 1-year high of $88.20. The business’s fifty day moving average price is $74.76 and its two-hundred day moving average price is $74.55. The company has a market capitalization of $13.54 billion, a P/E ratio of 9.58, a PEG ratio of 1.23 and a beta of 0.69.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same period last year, the company earned $1.34 earnings per share. The company’s quarterly revenue was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, research analysts forecast that Solventum Corporation will post 6.58 EPS for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.